Wang, Wenxian Gu, Xiaodong Wang, Liping Pu, Xingxiang Feng, Huijing Xu, Chunwei Lou, Guangyuan Shao, Lan Xu, Yibing Wang, Qian
...
Published in
Cancer immunology, immunotherapy : CII
Patients treated with immune checkpoint inhibitors (ICIs) often experience unique immune-related adverse events (irAEs), and the previous studies demonstrated an association between irAEs and better outcomes in patients with ICI treatment for advanced non-small cell lung cancer (NSCLC). However, the correlation between the occurrence of mild and se...
Arole, Vidya Shafi, Saba Challa, Bindu Parwani, Anil V Tozbikian, Gary Li, Zaibo
Published in
Clinical breast cancer
Very few studies have investigated mismatch repair (MMR) deficiency in breast carcinoma (BC) in clinical setting. Given the recent approval of Pembrolizumab for solid tumors with MMR deficiency, we screened clinically advanced breast carcinoma patients for immunotherapy by examining their MMR status. The cohort consisted of 163 clinical advanced BC...
Huang, Ta-Chen Liang, Cher-Wei Li, Yu-I Guo, Jhe-Cyuan Lin, Chia-Chi Chen, Ya-Jhen Cheng, Ann-Lii Hsu, Chih-Hung
Published in
Journal of cancer research and clinical oncology
Programmed death-ligand 1 (PD-L1) expression may influence the prognosis of patients with localized esophageal cancer. The current study compared the prognostic value of PD-L1 expression between tumor cells and immune cells. Archival esophageal tumor tissue samples were collected from patients who received paclitaxel and cisplatin-based neoadjuvant...
Yang, Zhao-ying Jiang, Cheng-wei Zhang, Wen-long Sun, Guang
Published in
Journal of Translational Medicine
Background Patients with triple-negative breast cancer (TNBC) are better responders to neoadjuvant chemotherapy; however, they are poor in the durability of response with decreased overall and progression-free survival. Methods Given that significant improvements have been reported with PD-L1-PD-1 blockade in different cancers, we evaluated the in ...
Li, Yulong Xin, Guang Li, Shiyi Dong, Yuman Zhu, Yuda Yu, Xiuxian Wan, Chengyu Li, Fan Wei, Zeliang Wang, Yilan
...
Published in
Frontiers in Pharmacology
Platelets play a central role in hemostasis and thrombosis, regulating the occurrence and development of thrombotic diseases, including ischemic stroke. Programmed death ligand 1 (PD-L1) has recently been detected in platelet, while the function of PD-L1 in platelets remain elusive. Our data reveal a novel mechanism for the role of PD-L1 on platele...
Luo, Cheng Wang, Songmao Shan, Wenjie Liao, Weijie Zhang, Shikuan Wang, Yanzhi Xin, Qilei Yang, Tingpeng Hu, Shaoliang Xie, Weidong
...
Published in
Frontiers in Immunology
Objective This study aims to identify prognostic factors for low-grade glioma (LGG) via different machine learning methods in the whole genome and to predict patient prognoses based on these factors. We verified the results through in vitro experiments to further screen new potential therapeutic targets. Method A total of 940 glioma patients from T...
Zhou, Huimin Bao, Guangfa Wang, Ziqiang Zhang, Buchuan Li, Dan Chen, Lixing Deng, Xiaoyun Yu, Bo Zhao, Jun Zhu, Xiaohua
...
Published in
EJNMMI Research
Background Adnectin is a protein family derived from the 10th type III domain of human fibronectin (10Fn3) with high-affinity targeting capabilities. Positron emission tomography (PET) probes derived from anti-programmed death ligand-1 (PD-L1) Adnectins, including 18F- and 68Ga-labeled BMS-986192, are recently developed for the prediction of patien...
Tampe, Désirée Kopp, Sarah Birgit Baier, Eva Hakroush, Samy Tampe, Björn
Published in
Frontiers in Medicine
Background Due to advances in cancer therapy, immune checkpoint inhibitors (ICIs) are new classes of drugs targeting programmed cell death protein 1-ligand 1 (PD-L1) or its receptor (PD-1) used in many cancer therapies. Acute interstitial nephritis (AIN) is a potential and deleterious immune-related adverse events (irAE) and the most common biopsy-...
Manenti, Susanna Orrico, Mario Masciocchi, Stefano Mandelli, Alessandra Finardi, Annamaria Furlan, Roberto
Published in
Frontiers in Neurology
The approval of immune checkpoint inhibitors (ICIs) by the Food and Drug Administration (FDA) led to an improvement in the treatment of several types of cancer. The main targets of these drugs are cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein-1/programmed death-ligand 1 pathway (PD-1/PD-L1), which are important inhibit...
Xu, Wenhua Wu, Linqing Xu, Mei Luo, Jia Chen, Gang
Published in
Frontiers in Oncology
Alcohol consumption in women enhances breast cancer incidence and ethanol is the main causal factor. Compromised host immunity through immunosuppression facilitates the development of many types of cancer, including breast cancer. Immune cells in breast tissues, particularly tumor-infiltrating CD8 cytotoxic T cells, play a critical role in the host...
